Conyac で依頼された翻訳結果を公開

Scor has been looking at the business for some months but was still not sure whether there was any deal to be done, according to one person familiar with the situation. Any deal would be complicated and was likely to involve both buying assets and writing a reinsurance contract over older liabilities, which made it difficult to assess the profitability and capital costs of a deal.

Denis Kessler, chief executive of Scor, declined to confirm the talks as the group reported 2010 results on Tuesday, although he did say its strategic plan was to take on “biometric risks” as it grows its life industry exposure, which accounted for 40 per cent of operating profits last year.

This is in contrast to the mainly investment-related risks that are attached to most US annuity products, which are savings products that usually provide some sort of return guarantee. Scor sold its US fixed annuity business last month to release capital for other life industry products.

Transamerica Re, which writes about $2bn in net premiums annually, has a significant annuity reinsurance business alongside its other mortality and capital release policy operations.

“We don’t know if Transamerica Re satisfies [our] acquisition criteria,” Mr Kessler told reporters.